UBS AM’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q3 | – | Sell |
-13,633
| Closed | -$133K | – | 2577 |
|
|
2017
Q2 | $133K | Buy |
13,633
+4,446
| +48% | +$43.4K | ﹤0.01% | 2311 |
|
|
2017
Q1 | $223K | Buy |
9,187
+3,836
| +72% | +$93K | ﹤0.01% | 2139 |
|
|
2016
Q4 | $172K | Sell |
5,351
-4,194
| -44% | -$135K | ﹤0.01% | 2161 |
|
|
2016
Q3 | $477K | Sell |
9,545
-33,554
| -78% | -$1.68M | ﹤0.01% | 2007 |
|
|
2016
Q2 | $1.83M | Sell |
43,099
-123,245
| -74% | -$5.23M | ﹤0.01% | 1393 |
|
|
2016
Q1 | $11M | Buy |
166,344
+5,588
| +3% | +$368K | 0.01% | 826 |
|
|
2015
Q4 | $9.99M | Sell |
160,756
-5,344
| -3% | -$332K | 0.01% | 870 |
|
|
2015
Q3 | $11.1M | Buy |
166,100
+54,488
| +49% | +$3.65M | 0.01% | 844 |
|
|
2015
Q2 | $10.9M | Buy |
111,612
+1,004
| +0.9% | +$97.7K | 0.01% | 869 |
|
|
2015
Q1 | $10.3M | Buy |
110,608
+1,658
| +2% | +$155K | 0.01% | 876 |
|
|
2014
Q4 | $9.69M | Buy |
108,950
+2,263
| +2% | +$201K | 0.01% | 879 |
|
|
2014
Q3 | $7.37M | Buy |
106,687
+4,372
| +4% | +$302K | 0.01% | 939 |
|
|
2014
Q2 | $5.87M | Hold |
102,315
| – | – | 0.01% | 996 |
|
|
2014
Q1 | $4.06M | Buy |
102,315
+1,843
| +2% | +$73.1K | ﹤0.01% | 1094 |
|
|
2013
Q4 | $4.22M | Buy |
100,472
+750
| +0.8% | +$31.5K | ﹤0.01% | 1041 |
|
|
2013
Q3 | $2.98M | Buy |
99,722
+95,159
| +2,085% | +$2.84M | ﹤0.01% | 1110 |
|
|
2013
Q2 | $242K | Buy |
+4,563
| New | +$242K | ﹤0.01% | 2151 |
|